Xavier Causse

TL;DR: The safety profile was poor and patients with platelet count ≤ 100,000/mm(3) and serum albumin <35 g/L should not be treated with the triple therapy, and the on-treatment virological response was high.

TL;DR: Treatment with direct-acting antivirals is associated with reduced risk for mortality and hepatocellular carcinoma and should be considered in all patients with chronic HCV infection.

TL;DR: It is concluded that 3 MU of interferon is a more effective dose than 1 MU for controlling disease activity in non-A, non-B chronic hepatitis patients and women and younger and noncirrhotic patients are more likely to respond.

TL;DR: The Compassionate Use of Protease Inhibitors in Viral C Cirrhosis (COCIR) study as mentioned in this paper investigated the effectiveness of the protease inhibitors peginterferon and ribavirin in treatment-experienced patients with hepatitis C virus (HCV) genotype 1 infection and cirrhosis.

TL;DR: It is concluded that a 6‐mo course of 3 MU or 1 MU interferon‐α2b causes slight but nonetheless significant regression of liver fibrosis as assessed on the basis of quantitative estimation of liver collagen, irrespective of other response criteria, whereas progression of liver Fibrosis can be observed in the absence of treatment.